185 related articles for article (PubMed ID: 8521414)
21. Mutations associated with familial melanoma impair p16INK4 function.
Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
[TBL] [Abstract][Full Text] [Related]
22. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4.
Suzuki T; Kitao S; Matsushime H; Yoshida M
EMBO J; 1996 Apr; 15(7):1607-14. PubMed ID: 8612584
[TBL] [Abstract][Full Text] [Related]
23. Expression of p16INK4a suppresses the unbounded and anchorage-independent growth of a glioblastoma cell line that lacks p16INK4a.
Higashi H; Suzuki-Takahashi I; Yoshida E; Nishimura S; Kitagawa M
Biochem Biophys Res Commun; 1997 Feb; 231(3):743-50. PubMed ID: 9070885
[TBL] [Abstract][Full Text] [Related]
24. A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells.
Kwon TK; Buchholz MA; Gabrielson EW; Nordin AA
Oncogene; 1995 Nov; 11(10):2077-83. PubMed ID: 7478527
[TBL] [Abstract][Full Text] [Related]
25. Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis.
Houldsworth J; Reuter V; Bosl GJ; Chaganti RS
Cell Growth Differ; 1997 Mar; 8(3):293-9. PubMed ID: 9056671
[TBL] [Abstract][Full Text] [Related]
26. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16Ink4a and counteracts its inhibitory activity to CDK4.
Suzuki T; Yoshida M
Leukemia; 1997 Apr; 11 Suppl 3():14-6. PubMed ID: 9209282
[TBL] [Abstract][Full Text] [Related]
27. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.
Parry D; Bates S; Mann DJ; Peters G
EMBO J; 1995 Feb; 14(3):503-11. PubMed ID: 7859739
[TBL] [Abstract][Full Text] [Related]
28. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.
Nobori T; Miura K; Wu DJ; Lois A; Takabayashi K; Carson DA
Nature; 1994 Apr; 368(6473):753-6. PubMed ID: 8152487
[TBL] [Abstract][Full Text] [Related]
29. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization.
Dreyling MH; Bohlander SK; Adeyanju MO; Olopade OI
Cancer Res; 1995 Mar; 55(5):984-8. PubMed ID: 7867008
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of growth of human leukemia cell lines by retrovirally expressed wild-type p16INK4A.
Gombart AF; Yang R; Campbell MJ; Berman JD; Koeffler HP
Leukemia; 1997 Oct; 11(10):1673-80. PubMed ID: 9324288
[TBL] [Abstract][Full Text] [Related]
31. Deletion and differential expression of p16INK4a in mouse lung tumors.
Belinsky SA; Swafford DS; Middleton SK; Kennedy CH; Tesfaigzi J
Carcinogenesis; 1997 Jan; 18(1):115-20. PubMed ID: 9054597
[TBL] [Abstract][Full Text] [Related]
32. p16ink4a gene and hematological malignancies.
Quesnel B; Preudhomme C; Fenaux P
Leuk Lymphoma; 1996 Jun; 22(1-2):11-24. PubMed ID: 8724524
[TBL] [Abstract][Full Text] [Related]
33. p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
Reymond A; Brent R
Oncogene; 1995 Sep; 11(6):1173-8. PubMed ID: 7566978
[TBL] [Abstract][Full Text] [Related]
34. Structure of the cyclin-dependent kinase inhibitor p19Ink4d.
Luh FY; Archer SJ; Domaille PJ; Smith BO; Owen D; Brotherton DH; Raine AR; Xu X; Brizuela L; Brenner SL; Laue ED
Nature; 1997 Oct; 389(6654):999-1003. PubMed ID: 9353127
[TBL] [Abstract][Full Text] [Related]
35. Differential expressions of cyclin A and the retinoblastoma gene product in histological subtypes of lung cancer cell lines.
Shimizu E; Zhao M; Shinohara A; Namikawa O; Ogura T; Masuda N; Takada M; Fukuoka M; Sone S
J Cancer Res Clin Oncol; 1997; 123(10):533-8. PubMed ID: 9393586
[TBL] [Abstract][Full Text] [Related]
36. p16INK4A participates in a G1 arrest checkpoint in response to DNA damage.
Shapiro GI; Edwards CD; Ewen ME; Rollins BJ
Mol Cell Biol; 1998 Jan; 18(1):378-87. PubMed ID: 9418885
[TBL] [Abstract][Full Text] [Related]
37. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study.
Sakaguchi M; Fujii Y; Hirabayashi H; Yoon HE; Komoto Y; Oue T; Kusafuka T; Okada A; Matsuda H
Int J Cancer; 1996 Feb; 65(4):442-5. PubMed ID: 8621224
[TBL] [Abstract][Full Text] [Related]
38. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines.
He J; Olson JJ; James CD
Cancer Res; 1995 Nov; 55(21):4833-6. PubMed ID: 7585516
[TBL] [Abstract][Full Text] [Related]
39. Infrequent alterations of the p16INK4A gene in liver cancer.
Kita R; Nishida N; Fukuda Y; Azechi H; Matsuoka Y; Komeda T; Sando T; Nakao K; Ishizaki K
Int J Cancer; 1996 Jul; 67(2):176-80. PubMed ID: 8760583
[TBL] [Abstract][Full Text] [Related]
40. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene.
Ichimura K; Schmidt EE; Goike HM; Collins VP
Oncogene; 1996 Sep; 13(5):1065-72. PubMed ID: 8806696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
